Table 1. Association between KIF20A expression and the clinicopathological features of 105 with patients NPC.
| Feature | Total | KIF20A | P-value | |
|---|---|---|---|---|
| Low expression | High expression | |||
| Age (years) | ||||
| ≥45 | 45 (42.9%) | 30 (55.6%) | 24 (44.4%) | 0.735† |
| <45 | 60(57.1%) | 30(58.8%) | 21(41.2%) | |
| Gender | ||||
| Male | 78 (74.3%) | 49 (62.8%) | 29 (37.2%) | 0.046† |
| Female | 27 (25.7%) | 11 (40.7%) | 16 (62.8%) | |
| Histologic classification | ||||
| U | 102 (97.1%) | 58 (56.9%) | 44 (43.1%) | 0.888* |
| D | 3 (2.9%) | 2 (66.7%) | 1 (33.3%) | |
| T classification | ||||
| 1 | 7 (6.7%) | 6 (85.7%) | 1 (14.3%) | 0.022† |
| 2 | 24 (22.9%) | 17 (70.8%) | 7 (29.2%) | |
| 3 | 52 (49.5%) | 29 (55.8%) | 23 (44.2%) | |
| 4 | 22 (21.0%) | 8(36.4%) | 14 (63.6%) | |
| N classification | ||||
| 0 | 17 (16.2%) | 16 (94.1%) | 1 (2.2%) | <0.001& |
| 1 | 50 (47.6%) | 36 (72%) | 14(28%) | |
| 2 | 27(25.7%) | 8(29.6%) | 19(70.4%) | |
| 3 | 11(10.5%) | 0 (0%) | 11(100%) | |
| Clinical stage | ||||
| I | 2(1.9%) | 2 (100.0%) | 0 (0.0%) | <0.001& |
| II | 19 (18.1%) | 17 (89.5%) | 2 (10.5%) | |
| III | 52 (49.5%) | 33 (63.5%) | 19(36.5%) | |
| IV | 32 (30.5%) | 8 (25.0%) | 24 (75.0%) | |
| Metastasis | ||||
| No | 89 (84.8%) | 57(64.0%) | 32 (36.0%) | 0.001† |
| Yes | 16 (15.2%) | 3(18.8%) | 13(81.2%) | |
| Vital status | ||||
| Alive | 91 (86.7%) | 58 (63.7%) | 33(36.3%) | 0.001* |
| Dead | 14 (13.3%) | 2 (14.3%) | 12 (85.7%) | |
| Treatment method | ||||
| Radiotherapy | 18(17.1%) | 14(77.8%) | 4(22.2%) | 0.052† |
| CCRT | 87(82.9%) | 46(52.9%) | 41(47.1%) | |
†P values, *P values, &P values were calculated with the chi-square test, Continuity Correlation and the Fisher’s exact test, respectively.
Abbreviations: NPC, nasopharyngeal carcinoma; U, undifferentiated non-keratinized carcinoma; D,differentiated non-keratinized carcinoma; CCRT, concurrent chemoradiotherapy.